Andrea Groß
0000-0003-1646-4531
National Cancer Institute
4 papers found
Refreshing results…
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
Missing publications? Search for publications with a matching author name.